10-K/A: CN Healthy Food Tech Group Corp. Faces Nasdaq Halt Amid CSRC Review

CN Healthy Food Tech Group Corp. reports significant revenue growth but faces a Nasdaq trading halt, pending China Securities Regulatory Commission review, alongside defaulted debt obligations.

Summary

• CN Healthy Food Tech Group Corp. (formerly Iron Horse Acquisition Corp.) filed an amendment to its 10-K for the fiscal year ended December 31, 2025, primarily to include XBRL information.
• The company experienced substantial revenue growth, increasing by 144.6% to $27.8 million in 2025 from $11.3 million in 2024.
• Despite revenue growth, trading of the company's common stock and warrants on Nasdaq has been suspended since October 1, 2025, due to a notification from the China Securities Regulatory Commission (CSRC) regarding an incomplete review process.
• The company has defaulted on three promissory notes totaling approximately $4.5 million as of December 31, 2025, and is in negotiations to extend maturity dates.
• The company's own production base commenced operations in October 2025, contributing 13% to annual revenue and strengthening control over quality and supply chain.
• Operating expenses increased significantly by 231.6% to $6.6 million in 2025, attributed to scaling operations, hiring, establishing sales and marketing functions, and costs associated with becoming a public company and the business combination.
• Net income increased by 110.5% to $8.4 million in 2025 from $4.0 million in 2024.
• As of December 31, 2025, the company held $33.0 million in cash and cash equivalents, which management believes is sufficient to cover its debts and ongoing operations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with caution due to the ongoing Nasdaq trading halt, pending CSRC approval, and defaulted promissory notes, despite revenue growth.

Positives

• Significant revenue growth of 144.6% to $27.8 million in 2025.
• Net income increased by 110.5% to $8.4 million in 2025.
• Successful launch and operation of its own production base since October 2025, contributing 13% to revenue.
• Strong cash position of $33.0 million as of December 31, 2025, deemed sufficient to cover debts and operations.
• Expansion of online live-streaming sales, which grew to 13.8% of revenue in 2025 from 6.0% in 2024.
• Establishment of a robust R&D system and collaborations with research institutions.
• Expansion of offline marketing channels to over 10,000 physical stores and distributor clients.

Negatives

• Ongoing trading halt on Nasdaq since October 1, 2025, due to CSRC review process.
• Default on three promissory notes totaling approximately $4.5 million as of December 31, 2025.
• Significant increase in operating expenses by 231.6% to $6.6 million in 2025.
• The company is an emerging growth company and has identified material weaknesses in its internal controls over financial reporting, including insufficient GAAP-experienced personnel and inadequate staffing for duty segregation.
• Reliance on a few key suppliers for procurement, with four suppliers contributing over 10% of total procurement in 2024.
• The company has not yet established insider trading policies and procedures.

Risks

• The Nasdaq trading halt may continue indefinitely, severely impacting liquidity and investor confidence.
• Failure to obtain CSRC approval for the listing could lead to sanctions, restrictions on operations, and potential delisting.
• The company's business operations are primarily in China and subject to complex and evolving PRC laws and regulations, including cybersecurity, data privacy, and foreign investment restrictions.
• Exchange rate fluctuations between RMB and USD could adversely affect financial results.
• Potential for intellectual property infringement claims and difficulties in protecting intellectual property rights in China.
• The company may face shareholder lawsuits if delisted from Nasdaq.
• The company's ability to meet future capital requirements may be impacted by its current financial situation and regulatory hurdles.
• The company has identified material weaknesses in internal controls over financial reporting, which could lead to future misstatements or errors.

Future Outlook

The company anticipates continued growth driven by its AI-powered biotechnology and health food products, expanding online and offline channels, and leveraging its new production base. However, the outlook is significantly clouded by the ongoing Nasdaq trading halt, pending CSRC approval, and defaulted debt obligations, which pose substantial risks to future financing and operations.

Management Comments

• The company's vision is to create a healthy world through AI technology and biotechnology.
• The group is committed to achieving its strategic goal of becoming a global leader in high-end health food innovation.
• Management believes its existing facilities are generally adequate to meet current needs, but anticipates seeking additional space in response to future growth requirements.
• Management has assessed that there are no material doubts regarding the company's ability to continue as a going concern, despite the Nasdaq trading suspension, defaulted promissory notes, and pending CSRC filing, due to sufficient cash on hand, ongoing negotiations with creditors, and strong operating performance.

Industry Context

StockSavvy.ai notes that the biotechnology high-end health food sector is highly competitive and innovation-driven, with increasing consumer demand for healthy and sustainable products. CN Healthy Food Tech Group Corp. competes with established domestic and international players, as well as emerging brands, by focusing on AI and biotechnology integration, a north-south operational layout, and expanding online and offline sales channels.

Comparison to Industry Standards

• The company aims to capture over 15% market share in the natural grain and processed health food markets.
• The company's production base is designed to meet modern production requirements and aims to build a state-of-the-art facility that meets industry benchmarks while integrating large-scale operations with smart technologies.
• The company's R&D efforts are supported by collaborations with authoritative domestic research institutions and experts, aligning with industry trends in advanced biotechnology health products.
• The company's marketing strategy leverages AI-powered digital human technology and virtual digital hosts for round-the-clock interactive engagement, reflecting industry adoption of advanced digital marketing tools.

Corporate Governance

Legal Proceedings

• The company is periodically involved in legal proceedings, legal actions, and claims arising in the normal course of business, including proceedings relating to intellectual property, safety and health, employment, and other matters. Management believes the outcome of these will not have a significant adverse effect.
• Potential shareholder lawsuits if securities are delisted from Nasdaq.

Related Party Transactions

• On May 30, 2024, Rosy Sea Holdings Limited contributed a building and land use rights valued at approximately $7.17 million to the Company.
• Compensation of $2,000,000 was payable to the Sponsor (Bengochea SPAC Sponsors I LLC) related to the business combination, with $1,000,000 accrued and $454,690 outstanding under promissory notes as of December 31, 2025.
• Mr. Jiang Zhenjun, a shareholder, paid acquisition-related fees totaling $1,715,250 on behalf of Iron Horse and various fees on behalf of CFI and CFI HK.
• The company has defaulted on promissory notes with the Sponsor and a non-related lender, with ongoing negotiations to extend maturity dates.

Stakeholder Impact

• Shareholders face significant adverse consequences due to the Nasdaq trading halt, including limited market quotes, reduced trading activity, and potential difficulty in selling holdings.
• Investors may experience significant adverse consequences if securities are delisted from Nasdaq, including liquidity and pricing constraints.
• The company's ability to raise additional capital may be impacted by its current financial situation and regulatory hurdles, affecting future growth and shareholder value.
• Employees are subject to government-mandated contribution plans for retirement, medical, and other welfare benefits in China.

Next Steps

• The company is awaiting further information from Nasdaq regarding the trading halt and clarification of matters with the CSRC.
• The company is in negotiations with creditors to extend the maturity dates of defaulted promissory notes.
• The company plans to implement remedial measures to address material weaknesses in internal controls over financial reporting.
• The company will continue to develop and market its health food products, leveraging AI and biotechnology.
• The company plans to establish a chain network of Traditional Chinese Medicine (TCM) health centers starting from 2025.
• The company intends to further establish a multi-account live streaming system combining the main brand account with vertical sub-accounts.

Key Dates

Recommendation

While the company shows strong revenue growth and profitability, the significant risks associated with the Nasdaq trading halt, pending CSRC approval, and defaulted debt obligations warrant a cautious approach. The potential for resolution exists, but the uncertainty is high. A 'hold' position allows investors to monitor developments without committing new capital or exiting existing positions prematurely.

Keywords

health food, biotechnology, AI technology, e-commerce, live streaming sales, supply chain, China operations, Nasdaq listing